CA2837312A1 - Modulateurs allosteriques du recepteur 5 du glutamate methabotropique et methodes d'utilisation associees - Google Patents

Modulateurs allosteriques du recepteur 5 du glutamate methabotropique et methodes d'utilisation associees Download PDF

Info

Publication number
CA2837312A1
CA2837312A1 CA2837312A CA2837312A CA2837312A1 CA 2837312 A1 CA2837312 A1 CA 2837312A1 CA 2837312 A CA2837312 A CA 2837312A CA 2837312 A CA2837312 A CA 2837312A CA 2837312 A1 CA2837312 A1 CA 2837312A1
Authority
CA
Canada
Prior art keywords
compound
cr4a
synthesis
esi
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2837312A
Other languages
English (en)
Inventor
Michele L. R. Heffernan
Larry Wendell Hardy
Frank Xinhe Wu
Lakshmi D. Saraswat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of CA2837312A1 publication Critical patent/CA2837312A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA2837312A 2011-05-26 2012-05-25 Modulateurs allosteriques du recepteur 5 du glutamate methabotropique et methodes d'utilisation associees Abandoned CA2837312A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490402P 2011-05-26 2011-05-26
US61/490,402 2011-05-26
PCT/US2012/039639 WO2012162635A1 (fr) 2011-05-26 2012-05-25 Modulateurs des récepteurs 5 métabotropiques du glutamate et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
CA2837312A1 true CA2837312A1 (fr) 2012-11-29

Family

ID=47217784

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2837312A Abandoned CA2837312A1 (fr) 2011-05-26 2012-05-25 Modulateurs allosteriques du recepteur 5 du glutamate methabotropique et methodes d'utilisation associees

Country Status (4)

Country Link
US (1) US10533000B2 (fr)
AU (2) AU2012258618B2 (fr)
CA (1) CA2837312A1 (fr)
WO (1) WO2012162635A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948447B1 (fr) 2013-01-23 2016-09-21 Astrazeneca AB Composés chimiques
TWI649310B (zh) 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 乙炔基衍生物
PL3322701T3 (pl) 2015-07-15 2019-09-30 F. Hoffmann-La Roche Ag Pochodne etynylowe jako modulatory metabotropowego receptora glutaminianowego
WO2017035224A1 (fr) 2015-08-24 2017-03-02 Cody Laboratories, Inc. Synthèse de chlorhydrate de lévométhadone ou de chlorhydrate de dextrométhadone et leurs méthodes d'utilisation
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
CA3030788A1 (fr) 2016-07-18 2018-01-25 F. Hoffmann-La Roche Ag Derives d'ethynyle
US11274100B2 (en) 2017-06-21 2022-03-15 Daiichi Sankyo Company, Limited EP300/CREBBP inhibitor
WO2019025250A1 (fr) 2017-08-04 2019-02-07 Basf Se Trifluorométhyloxadiazoles substitués permettant de lutter contre des champignons phytopathogènes
WO2020007964A1 (fr) * 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd Dérivés de 2-(2-azabicyclo [3.1.0] hexan-1-yl)-1h-benzimidazole
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
EP4382527A1 (fr) * 2021-08-05 2024-06-12 Zhejiang Hisun Pharmaceutical Co., Ltd. Dérivé d'acétylène aromatique, son procédé de préparation et son utilisation
CN114292202A (zh) * 2021-11-19 2022-04-08 四川科宏达集团有限责任公司 一种高抗菌活性氨基酸两性表面活性剂及其制备方法
WO2024067812A1 (fr) * 2022-09-28 2024-04-04 浙江海正药业股份有限公司 Dérivé d'acétylène aromatique, son procédé de préparation et son utilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US260233A (en) * 1882-06-27 Rack-motion for printing-presses
FR1547502A (fr) 1966-08-15 1968-11-29 Ciba Geigy Nouveaux dérivés du tolane, leur emploi et leur procédé de préparation
DOP1981004033A (es) * 1980-12-23 1990-12-29 Ciba Geigy Ag Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
CA1260948A (fr) 1984-12-05 1989-09-26 E. I. Du Pont De Nemours And Company Derives d'aminomethyloxo-oxazolidinylbenzene, agents antibacteriens
US4582836A (en) 1985-01-09 1986-04-15 Mcneilab, Inc. Octahydroindolizine compounds useful as analgesics
US5486517A (en) 1994-05-10 1996-01-23 Warner-Lambert Company Benzimidazoles and imidazopyridines as central nervous system agents
SE9801923D0 (sv) 1998-05-29 1998-05-29 Independent Pharmaceutical Ab Nicotine vaccine
US6417187B2 (en) 2000-04-14 2002-07-09 Dow Agrosciences Llc 1,2,4-triazole based compounds that can be used as insecticides or acaricides and processes
US20090048301A1 (en) 2003-07-09 2009-02-19 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
JP2007045752A (ja) * 2005-08-10 2007-02-22 Takeda Chem Ind Ltd ５員芳香族複素環誘導体、その製造法および用途
MX2011003239A (es) 2008-09-26 2011-04-28 Merck Sharp & Dohme Nuevos derivados de bencimidazol ciclicos utiles como agentes anti-diabeticos.

Also Published As

Publication number Publication date
AU2012258618B2 (en) 2017-05-25
AU2017216495A1 (en) 2017-08-31
WO2012162635A8 (fr) 2013-12-27
US10533000B2 (en) 2020-01-14
WO2012162635A1 (fr) 2012-11-29
US20140221332A1 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
AU2012258618B2 (en) Metabotropic glutamate receptors 5 modulators and methods of use thereof
CN111601799B (zh) 作为Il-17调节剂的稠合咪唑衍生物
CA2784830C (fr) Composes pour le traitement des troubles medies par le recepteur metabotropique 5 du glutamate, et leurs methodes d'utilisation
TWI804003B (zh) Tlr7/8拮抗劑及其用途
AU2012258618A1 (en) Metabotropic glutamate receptors 5 modulators and methods of use thereof
US10640510B2 (en) Metabotrophic glutamate receptor 5 modulators and methods use thereof
EP3134408B1 (fr) Inhibiteurs du facteur xia
ES2459496T3 (es) Diaza-espiro[5.5]undecanos como antagonistas del receptor de orexina
RU2332412C2 (ru) Производные пиразола
EA039783B1 (ru) ПРОИЗВОДНЫЕ ТИРОЗИНАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
KR20170129729A (ko) 중추 신경계 질환을 치료하기 위한 융합된 다이하이드로-4h-피라졸로[5,1-c][1,4]옥사진일 화합물 및 유사체
IL273839B (en) Benzimidazole derivatives and their uses
WO2016100349A2 (fr) Composés azahétérocycliques bicycliques utilisés comme antagonistes des récepteurs nmda nr2b
CA3074059A1 (fr) Derives de 2-azabicyclo[3.1.1]heptane et de 2-azabicyclo[3.2.1]octane substitues en tant qu'antagonistes du recepteur de l'orexine
AU2021219710A1 (en) Heterocyclic PAD4 inhibitors
AU2021249109A1 (en) N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists
CA3185597A1 (fr) Inhibiteurs de la kallicreine plasmatique
BR122023025931A2 (pt) Compostos para o tratamento de condições associadas com atividade do receptor apj, composição farmacêutica compreendendo os referidos compostos, e seus usos
TW201910325A (zh) 吲哚衍生物及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170105

FZDE Discontinued

Effective date: 20201229